Substituted 2H-1,3-benzoxazin-4(3H)-ones

Details Substituted 2H-1,3-benzoxazin-4(3H)-ones Substituted 2H-1,3-benzoxazin-4(3H)-ones

2007-04-17

2007-04-17

Habte, Kahsay (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S071000, C544S092000

Reexamination Certificate

active

11236051

ABSTRACT:
Substituted benzoxazin-4(3H)-ones are provided which are useful for treating thrombosis and for reducing the likelihood and/or severity of a secondary ischemic event in a patient.

REFERENCES:
patent: 5288726 (1994-02-01), Koike et al.
patent: 6248729 (2001-06-01), Coniglio et al.
patent: 6509348 (2003-01-01), Ogletree
patent: 6689786 (2004-02-01), Scarborough et al.
patent: 6995156 (2006-02-01), Bryant et al.
patent: 2003/0109543 (2003-06-01), Ogletree
patent: 2003/0124626 (2003-07-01), Takasaki et al.
patent: WO 99/05144 (1999-02-01), None
patent: WO 99/36425 (1999-07-01), None
patent: WO 098856 (2002-12-01), None
André, P. et al., “Anticoagulants (Thrombin Inhibitors) and Aspirin Synergize With P2Y12Receptor Antagonism in Thrombosis,”Circulation(Nov. 25, 2003), pp. 2697-2703.
André, P. et al., “P2Y12Regulates Platelet Adhesion/Activation, Thrombus Growth, and Thrombus Stability in Injured Arteries,”J. Clinical Investigation(Aug. 2003), vol. 112:3.
Berge, S. M. et al., “Pharmaceutical Salts,”J. Pharm. Sciences(Jan. 1977), vol. 66:1.
Dorsam, R.T. et al., “Central Role of the P2Y12Receptor in Platelet Activation,”J. Clinical Investigation(Feb. 2004), vol. 113:3.
Fox, K.A.A. et al., “Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non-ST-Elevation Acute Coronary Syndrome,”Circulation(Sep. 7, 2004), pp. 1202-1208.
Fratantoni, J. C. et al., “Measuring Platelet Aggregation with Microplate Reader—A new Technical Approach to Platelet Aggregation Studies,”Platelet Aggregation with Microplates, (1989) vol. 94:5, pp. 613-617.
Fredholm, B. B. et al., “Towards a Revised Nomenclature for P1 and P2 Receptors,”TiPS(Mar. 1997), vol. 18, pp. 79-82.
Gent, M. et al., “A Randomised, Blinded, Trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE),”The Lancet(Nov. 16, 1996), vol. 348, pp. 1329-1339.
Hechler, B. et al., “The P2Y1Receptor is Necessary for Adenosine 5′-Diphosphate-Induced Platelet Aggregation,”Blood(Jul. 1, 1998), vol. 92:1, pp. 152-159.
Hollopeter, G. et al., Identification of the Platelet ADP Receptor Targeted by Antithrombotic Drugs,Nature(Jan. 11, 2001), vol. 409, pp. 202-207.
Humphries, R. G. et al., A Novel Series of P2TPurinoceptor Antagonists: Definition of the Role of ADP in Arterial Thrombosis,TiPS(Jun. 1995), vol. 16, pp. 179-181.
Ingall, A. H. et al., Antagonists of the Platelet P2TReceptor: A Novel Approach to Antithrombotic Therapy,J. Med. Chem. (1999), vol. 42, pp. 213-220.
Jantzen, H. et al., “Evidence for Two Distinct G-Protein-Coupled ADP Receptors Mediating Platelet Activation,”Throm Haemost(1999), vol. 81, pp. 111-117.
King, B. F. et al., “Metabotropic Receptors for ATP and UTP: Exploring the Correspondence Between Native and Recombinant Nucleotide Receptors,”TiPS(Dec. 1998), vol. 19, pp. 506-514.
Kunapuli, S.P. et al., “P2Receptor Subtypes in the Cardiovascular System,”Biochem. J.(1998), vol. 336, pp. 513-523.
Kunapuli, S.P., Multiple P2 Receptor Subtypes on Platelets: A New Interpretation of Their Function,TiPS(Oct. 1998), vol. 19, pp. 391-394.
Mehta, S. R. et al., “Effects of Pretreatment with Clopidogrel and Aspirin Followed by Long-Term Therapy in Patients Undergoing Percutaneous Coronary Intervention: The PCI-CURE Study,”The Lancet(Aug. 18, 2001), vol. 358, pp. 527-533.
Mills, D. C. B., “ADP Receptors on Platelets,”Thrombosis and Haemostasis(1996), vol. 76:6, pp. 835-856.
Quinn, M. J. et al., “Ticlopidine and Clopidogrel,”Circulation(1999); vol. 100, pp. 1667-1672.
van Gestel, M.A. et al., “In Vivo Blockade of Platelet ADP Receptor P2Y12Reduces Embolus and Thrombus Formation but Not Thrombus Stability,”Arterioscler Thromb Vasc Biol. (2003), vol. 23, pp. 518-523.
Wiviott, S. D. et al., Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y12Antagonist, with Clopidogrel in Percutaneous Coronary Intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial,Circulation(2005), vol. 111, pp. 3366-3373.
Yusuf, S. et al., “Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes Without ST-Segment Elevation: The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators,”N Engl J. Med(Aug. 16, 2001), vol. 345:7, pp. 494-502.

Affiliated with

Also associated with

Rating

Substituted 2H-1,3-benzoxazin-4(3H)-ones does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted 2H-1,3-benzoxazin-4(3H)-ones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 2H-1,3-benzoxazin-4(3H)-ones will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3751437